[HTML][HTML] Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application
M Xu, P Qi, X Du - Modern pathology, 2014 - Elsevier
Long non-coding RNAs (lncRNAs) are a class of newly identified non-coding RNA
molecules that are emerging as key regulators of tumor initiation and development …
molecules that are emerging as key regulators of tumor initiation and development …
Long non-coding RNAs as potential novel prognostic biomarkers in colorectal cancer
E Saus, A Brunet-Vega, S Iraola-Guzmán… - Frontiers in …, 2016 - frontiersin.org
Colorectal cancer (CRC) is the fourth most common cause of death worldwide. Surgery is
usually the first line of treatment for patients with CRC but many tumors with similar …
usually the first line of treatment for patients with CRC but many tumors with similar …
Roles of long non-coding RNAs in colorectal cancer tumorigenesis: A Review
H Siddiqui, A Al-Ghafari… - Molecular and …, 2019 - spandidos-publications.com
Long non‑coding RNAs (lncRNAs) are newly identified potential biological and gene
regulators. Similar to other cell‑free circulating cancer‑related nucleic acids, lncRNAs are …
regulators. Similar to other cell‑free circulating cancer‑related nucleic acids, lncRNAs are …
Long non-coding RNAs in colorectal cancer: novel oncogenic mechanisms and promising clinical applications
Y Yang, X Yan, X Li, Y Ma, A Goel - Cancer letters, 2021 - Elsevier
Colorectal cancer (CRC) is the third most common malignancy and ranks as the second
leading cause of cancer-related deaths worldwide. Despite the improvements in CRC …
leading cause of cancer-related deaths worldwide. Despite the improvements in CRC …
The potential relevance of long non-coding RNAs in colorectal cancer pathogenesis and treatment: A review focus on signaling pathways
Colorectal cancer (CRC) is one of the most frequent cancers in incidence and mortality.
Despite advances in cancer biology, molecular genetics, and targeted treatments, CRC …
Despite advances in cancer biology, molecular genetics, and targeted treatments, CRC …
Discovery and validation of clinically relevant long non-coding RNAs in colorectal cancer
M Snyder, S Iraola-Guzman, E Saus, T Gabaldon - Cancers, 2022 - mdpi.com
Simple Summary Recent efforts in biomedical research have focused on the identification of
molecular biomarkers to improve the diagnosis, prognosis and eventually treatment of the …
molecular biomarkers to improve the diagnosis, prognosis and eventually treatment of the …
Long noncoding RNAs: novel players in colorectal cancer
D Han, M Wang, N Ma, Y Xu, Y Jiang, X Gao - Cancer letters, 2015 - Elsevier
Colorectal cancer (CRC) is the most common type of cancer in the world. Despite its
commonness, the underlying mechanism of CRC is not completely understood. Long …
commonness, the underlying mechanism of CRC is not completely understood. Long …
Involvement of long non-coding RNA in colorectal cancer: From benchtop to bedside
LC Ye, DX Zhu, JJ Qiu, J Xu, YE Wei - Oncology letters, 2015 - spandidos-publications.com
Colorectal cancer (CRC) is one of the greatest threats to public health. Recent advances in
whole-genome transcriptome analyses have enabled the identification of numerous …
whole-genome transcriptome analyses have enabled the identification of numerous …
Mechanisms of long non‐coding RNA function in colorectal cancer tumorigenesis
A Poursheikhani, MR Abbaszadegan… - Asia‐Pacific Journal …, 2021 - Wiley Online Library
Colorectal cancer (CRC) is one of the most common cancers globally. Although a variety of
CRC screening methods have been developed, many patients are diagnosed at advanced …
CRC screening methods have been developed, many patients are diagnosed at advanced …
Long noncoding RNA in digestive tract cancers: function, mechanism, and potential biomarker
S Zeng, YF Xiao, B Tang, CJ Hu, R Xie, SM Yang… - The …, 2015 - academic.oup.com
Digestive tract cancers (DTCs) are a leading cause of cancer-related death worldwide.
Current therapeutic tools for advanced stage DTCs have limitations, and patients with early …
Current therapeutic tools for advanced stage DTCs have limitations, and patients with early …